ABSTRACT
BACKGROUND: Multiple endocrine neoplasia type 1 (MEN 1) syndrome is a rare, complex genetic disorder characterized by increased predisposition to tumorigenesis in multiple endocrine and non-endocrine tissues. Diagnosis and management of MEN 1 syndrome is challenging due to its vast heterogeneity in clinical presentation. CASE PRESENTATION: A 23-year-old female, previously diagnosed with Polycystic Ovarian Syndrome (PCOS) and pituitary microprolactinoma presented with drowsiness,confusion and profuse sweating developing over a period of one day. It was preceded by fluctuating, hallucinatory behavior for two weeks duration. There was recent increase in appetite with significant weight gain. There was no fever, seizures or symptoms suggestive of meningism. Her Body mass index(BMI) was 32 kg/m2.She had signs of hyperandrogenism. Multiple cutaneous collagenomas were noted on anterior chest and abdominal wall. Her Glasgow Coma Scale was 9/15. Pupils were sluggishly reactive to light. Tendon reflexes were exaggerated with up going planter reflexes. Moderate hepatomegaly was present. Rest of the clinical examination was normal. Laboratory evaluation confirmed endogenous hyperinsulinaemic hypoglycaemia suggestive of an insulinoma. Hypercalcemia with elevated parathyroid hormone level suggested a parathyroid adenoma. Presence of insulinoma, primary hyperparathyroidism and pituitary microadenoma, in 3rd decade of life with characteristic cutaneous tumours was suggestive of a clinical diagnosis of MEN 1 syndrome. Recurrent, severe hypoglycaemia complicated with hypoglycaemic encephalopathy refractory to continuous, parenteral glucose supplementation and optimal pharmacotherapy complicated the clinical course. Insulinoma was localized with selective arterial calcium stimulation test. Distal pancreatectomy and four gland parathyroidectomy was performed leading to resolution of symptoms. CONCLUSIONS: Renal calculi or characteristic cutaneous lesions might be the only forewarning clinical manifestations of an undiagnosed MEN 1 syndrome impending a life-threatening presentation. Comprehensive management of MEN 1 syndrome requires multi-disciplinary approach with advanced imaging modalities, advanced surgical procedures and long-term follow up due to its heterogeneous presentation and the varying severity depending on the disease phenotype.
Subject(s)
Hypoglycemia , Insulinoma , Multiple Endocrine Neoplasia Type 1 , Adult , Female , Humans , Hypoglycemia/diagnosis , Hypoglycemia/etiology , Hypoglycemia/surgery , Insulinoma/diagnosis , Insulinoma/etiology , Insulinoma/surgery , Multiple Endocrine Neoplasia Type 1/complications , Multiple Endocrine Neoplasia Type 1/diagnosis , Multiple Endocrine Neoplasia Type 1/surgery , Pancreatectomy , Parathyroidectomy , Young AdultABSTRACT
Pancreatic neuroendocrine tumors are rare with an incident rate of 5 cases per million individuals. Tuberous sclerosis complex is an autosomal dominant disease. This disease involves multisystem and occurs in one out of every 6,000-10,000 individuals. In this study, we describe a 47-year-old male known tuberous sclerosis patient with an insulinoma. The tumor was incidentally detected in follow-up imaging for a previous ampulla of Vater tubular adenoma. However, the patient reported symptoms of hypoglycemia. The insulinoma was enucleated successfully. Histopathology revealed a well-differentiated, grade one neuroendocrine tumor measuring around 2 cm in diameter. Seven cases were reported in the literature of tuberous sclerosis-associated insulinoma. The 7 reported cases had different hypoglycemia related symptoms. The reported tumors varied in size and location on the pancreas. This paper details the eighth case worldwide where an insulinoma occurred in a tuberous sclerosis patient.
Subject(s)
Insulinoma/diagnosis , Insulinoma/surgery , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/surgery , Tuberous Sclerosis/complications , Ampulla of Vater , Humans , Hypoglycemia/etiology , Incidental Findings , Insulinoma/etiology , Laparotomy/methods , Male , Middle Aged , Pancreatectomy/methods , Pancreatic Neoplasms/etiology , Surgery, Computer-AssistedABSTRACT
Resistin promotes hypothalamic neuroinflammation and insulin resistance through Toll like receptor 4 (TLR4), this hormone is thought to be a link between obesity and insulin-resistance. Indeed, resistin plasma levels are higher in obese and insulin resistant subjects. However, the impact of maternal resistin on the predisposition of offspring to hypothalamic neuroinflammation is unknown. Here, female mice were treated with resistin during gestation/lactation periods, then hypothalamic neuroinflammation was investigated in male offspring at p28 and p90. At p28, resistin increased the expression of inflammation markers (IL6, TNFα and NFκB) and TLR4 in the hypothalamus and decreased both hypothalamic insulin and leptin receptors' expression. The hypothalamic up-regulation IL6, TNFα and TLR4 was sustained until p90 promoting most likely hypothalamic inflammation. Maternal resistin also increased IL6 and TNFα in the adipose tissue of offspring at p90 associated with a higher body weight gain. In contrast, liver and muscle were not affected. These findings reveal that the augmentation of maternal resistin during gestation and lactation promotes hypothalamic and adipose tissue inflammation of offspring as evidenced by sustained increase of inflammation markers from weaning to adulthood. Thus, maternal resistin programs offspring hypothalamic and adipose tissue inflammation predisposing then offspring to body weight gain.
Subject(s)
Glucose Intolerance/etiology , Hypothalamus/immunology , Inflammation/etiology , Insulin Resistance , Insulinoma/etiology , Resistin/adverse effects , Weight Gain/drug effects , Animals , Animals, Newborn , Body Weight , Female , Glucose Intolerance/metabolism , Glucose Intolerance/pathology , Hypothalamus/drug effects , Hypothalamus/metabolism , Hypothalamus/pathology , Inflammation/metabolism , Inflammation/pathology , Inflammation Mediators/metabolism , Insulinoma/metabolism , Insulinoma/pathology , Lactation , Leptin/metabolism , Male , Maternal Nutritional Physiological Phenomena , Mice , Pregnancy , Resistin/administration & dosage , WeaningABSTRACT
Altered metabolism is implicated in the pathogenesis of beta-cell failure in type 2 diabetes (T2D). Plasma and tissue levels of ceramide species play positive roles in inflammatory and oxidative stress responses in T2D. However, oxidative targets and mechanisms underlying ceramide signaling are unclear. We investigated the role of CD36-dependent redoxosome (redox-active endosome), a membrane-based signaling agent, in ceramide-induced beta-cell dysfunction and failure. Exposure of beta cells to C2-ceramide (N-acetyl-sphingosine) induced a CD36-dependent non-receptor tyrosine kinase Src-mediated redoxosome (Vav2-Rac1-NOX) formation. Activated Rac1-GTP-NADPH oxidase complex induced c-Jun-N-terminal kinase (JNK) activation and nuclear factor (NF)-kB transcription, which was associated with thioredoxin-interacting protein (TXNIP) upregulation and thioredoxin activity suppression. Upregulated JNK expression induced p66Shc serine36 phosphorylation and peroxiredoxin-3 hyperoxidation, causing beta-cell apoptosis via mitochondrial dysfunction. CD36 inhibition by sulfo-N-succinimidyl oleate (SSO) or CD36 siRNA blocked C2-ceramide-induced redoxosome activation, thereby decreasing JNK-dependent p66Shc serine36 phosphorylation. CD36 inhibition downregulated TXNIP expression and promoted thioredoxin activity via enhanced thioredoxin reductase activity, which prevented peroxiredoxin-3 oxidation. CD36 inhibition potentiated glucose-stimulated insulin secretion and prevented beta-cell apoptosis. Our results reveal a new role of CD36 during early molecular events that lead to Src-mediated redoxosome activation, which contributes to ceramide-induced pancreatic beta-cell dysfunction and failure.
Subject(s)
CD36 Antigens/metabolism , Ceramides/pharmacology , Gene Expression Regulation/drug effects , Insulinoma/pathology , Oxidative Stress , Src Homology 2 Domain-Containing, Transforming Protein 1/metabolism , Animals , Apoptosis , CD36 Antigens/genetics , Glucose/pharmacology , Insulinoma/etiology , Insulinoma/metabolism , Oxidation-Reduction , Pancreatic Neoplasms/etiology , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Phosphorylation , Rats , Signal Transduction , Src Homology 2 Domain-Containing, Transforming Protein 1/geneticsABSTRACT
BACKGROUND: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years. The occurrence of clinically relevant MEN1 organ manifestations in children (≤18 years) was evaluated. METHODS: Two prospective collected databases of MEN1 patients (n = 166) who underwent annual screening were retrospectively analyzed for organ manifestations in MEN1 patients ≤18 years. The follow-up was based on the most recent screening examination until December 2015. RESULTS: Twenty [11 females, 9 males, (12%)] of 166 MEN1 patients were diagnosed with at least one organ manifestation at age ≤18 years. The most frequent manifestation was mild asymptomatic pHPT (n = 9, 45%, age range 8-18 years). Eight (40%) young patients had pNENs (three non-functioning pNENs, five insulinomas, age range 9-18 years). All five insulinomas were diagnosed based on hypoglycemic symptoms. The other organ manifestations were asymptomatic pituitary adenomas in six patients (30%, age range 15-18 years) and a bronchial carcinoid in one 15-year-old patient. Only six (30%) patients ≤18 years had clinically relevant organ manifestations. CONCLUSION: Symptomatic or severe manifestations in MEN1 patients rarely occur below the age of 16 years. With regard to psychological burden and cost-effectiveness, routine screening of asymptomatic MEN1 patients should be postponed at least until the age of 16 years.
Subject(s)
Multiple Endocrine Neoplasia Type 1/diagnosis , Adolescent , Child , Female , Humans , Insulinoma/etiology , Male , Multiple Endocrine Neoplasia Type 1/complications , Pancreatic Neoplasms/etiology , Pituitary Neoplasms/etiology , Prospective Studies , Retrospective StudiesABSTRACT
Many reports exist on hyperinsulinemic hypoglycemia after bariatric surgery, which can result in persistence of the metabolic syndrome in patients who have undergone these procedures. While the noninsulinoma pancreatogenous hypoglycemia syndrome, or nesidioblastosis, has garnered increased attention in these patients, its presentation is similar to patients with an insulinoma and this entity must therefore be evaluated and ruled out. Herein, we present a patient who developed symptoms of hypoglycemia 7 years after Roux-en-Y gastric bypass surgery. While a diagnosis of insulinoma was entertained, his laboratory values were indeterminate and imaging localization was inconclusive. Because of significant medical comorbidities, he was managed symptomatically until imaging ultimately localized a lesion in the pancreatic uncinate process consistent with an insulinoma. He subsequently underwent resection and remains disease and symptom free 1 year after surgery. This case demonstrates the diagnostic and imaging dilemma in patients with hypoglycemia after bariatric surgery and should be of interest to anyone who cares for these patients.
Subject(s)
Gastric Bypass/adverse effects , Hypoglycemia/diagnostic imaging , Insulinoma/diagnostic imaging , Insulinoma/etiology , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/etiology , Aged , Humans , Hypoglycemia/etiology , Insulinoma/pathology , Male , Obesity, Morbid/surgery , Pancreatic Neoplasms/pathology , Tomography, X-Ray ComputedABSTRACT
Multiple Endocrine Neoplasia (MEN) is a condition in which several endocrine organs of an individual are affected by adenoma, hyperplasia and less often carcinoma, either simultaneously or at different stages of life. Two existing syndromes, MEN1 and MEN2 (2A, 2B), in literature is also mentioned MEN4, are associated also with other non-endocrine disorders. MEN1 (Wermer syndrome) affects the pituitary, parathyroid, and pancreatic area. 95 % of patients show very early manifestation of hyperparathyroidism, often before 40 years of age. Multiple adenomas gradually involve all four parathyroid glands. The first clinical sign of MEN1 includes recurrent nephrolithiasis. The second most frequent manifestation of MEN1 is pancreatic area (pancreas, stomach and duodenum), again multiple malignancies of varying degree which can metastasize. Most often gastrinomas and insulinomas are involved. Pituitary adenomas occur in about one third of MEN1 patients and tend to be larger and less responsive to treatment. Tumors appearing most often are prolactinomas, tumors producing growth hormone, or afunctional adenomas. The other endocrine tumors include carcinoids and adrenal lesions. In the last year we have registered four MEN1 syndrome patients in our center and one patient has been already followed since 2008. In four out of five patients, nephrolithiasis after 30 years of age was the first clinical symptom, but only one of theses cases resulted in MEN1 diagnosis. In all patients, the clinical symptoms intensified and the diagnosis was established between 36 and 40 years of age. A crutial factor is a cooperation with the urology examination of kidney stones formation in young individuals with nephrolithiasis in order to reveal the potential cases of MEN1 syndrome very early on. Consider the MEN1 genetic diagnostics if recurrent primary hyperparathyroidism or recurrent gastroduodenal ulcer disease appear in patients under 40 years of age.Key words: carcinoid - gastrinoma - hyperparathyroidism - insulinoma - MEN1 - multiple endocrine neoplasia - nefrolithiasis - neuroendocrine tumor - pancreatic area - pituitary gland.
Subject(s)
Adenoma/diagnosis , Gastrinoma/diagnosis , Insulinoma/diagnosis , Multiple Endocrine Neoplasia Type 1/diagnosis , Parathyroid Neoplasms/diagnosis , Pituitary Neoplasms/diagnosis , Prolactinoma/diagnosis , Adenoma/etiology , Adult , Gastrinoma/etiology , Humans , Hyperparathyroidism/diagnosis , Hyperparathyroidism/etiology , Insulinoma/etiology , Multiple Endocrine Neoplasia Type 1/complications , Nephrolithiasis/etiology , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/etiology , Parathyroid Neoplasms/etiology , Peptic Ulcer/etiology , Pituitary Neoplasms/etiology , Prolactinoma/etiologyABSTRACT
Diabetic retinopathy and age-related macular degeneration are the leading causes of blindness in Western populations. Although it is a matter of controversy, large-scale population-based studies have reported increased prevalence of age-related macular degeneration in patients with diabetes or diabetic retinopathy. We hypothesized that metabolic syndrome, one of the major risk factors for type 2 diabetes, would represent a favorable environment for the development of choroidal neovascularization, the main complication of age-related macular degeneration. The fructose-fed rat was used as a model for metabolic syndrome in which choroidal neovascularization was induced by laser photocoagulation. Male Brown Norway rats were fed for 1, 3, and 6 months with a standard equilibrated chow diet or a 60%-rich fructose diet (nâ=â24 per time point). The animals expectedly developed significant body adiposity (+17%), liver steatosis at 3 and 6 months, hyperleptinemia at 1 and 3 months (two-fold increase) and hyperinsulinemia at 3 and 6 months (up to two-fold increase), but remained normoglycemic and normolipemic. The fructose-fed animals exhibited partial loss of rod sensitivity to light stimulus and reduced amplitude of oscillatory potentials at 6 months. Fructose-fed rats developed significantly more choroidal neovascularization at 14 and 21 days post-laser photocoagulation after 1 and 3 months of diet compared to animals fed the control diet. These results were consistent with infiltration/activation of phagocytic cells and up-regulation of pro-angiogenic gene expression such as Vegf and Leptin in the retina. Our data therefore suggested that metabolic syndrome would exacerbate the development of choroidal neovascularization in our experimental model.
Subject(s)
Choroidal Neovascularization/etiology , Metabolic Syndrome/complications , Retina/physiopathology , Visual Acuity , Adipose Tissue/metabolism , Angiography/methods , Animals , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Diet/adverse effects , Electroretinography/drug effects , Fatty Acids/metabolism , Fatty Liver/etiology , Fructose/administration & dosage , Gene Expression/drug effects , Humans , Insulinoma/etiology , Laser Coagulation/adverse effects , Male , Metabolic Syndrome/etiology , Rats, Inbred BN , Retina/drug effects , Retina/metabolism , Retinal Rod Photoreceptor Cells/drug effects , Reverse Transcriptase Polymerase Chain ReactionSubject(s)
Insulinoma/diagnosis , Obesity/complications , Pancreatic Neoplasms/diagnosis , Unconsciousness/complications , Vertebrobasilar Insufficiency/diagnosis , Aged , Diagnosis, Differential , Diagnostic Errors , Humans , Insulinoma/etiology , Male , Pancreatic Neoplasms/etiology , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Hypoglycemia secondary to ectopic insulin secretion of non-pancreatic tumors is rare. CASE PRESENTATION: We describe a middle aged woman with recurrent hypoglycemia. On evaluation, she was detected to have hyperinsulinemic hypoglycemia and right sided renal mass lesion. 68Ga-Dotanoc and 99mTc-HYNICTOC scans confirmed the intrarenal mass to be of neuroendocrine origin. Right nephrectomy was done and it turned out to be an insulin secreting neuroendocrine tumour. Neuroendocrine nature of this tumour was further confirmed by ultra-structural examination. Her hypoglycemia did not recur after resection of this tumour. CONCLUSION: Few cases of ectopic insulin secretion have been reported though some are not proven convincingly. This case addresses all the issues raised in previous case reports and proves by clinical, laboratory, functional imaging and immunohistochemical analysis that ectopic origin of insulin by non-pancreatic tumors does occur. To our knowledge, this is the first reported case of ectopic insulinoma arising from the kidney.
Subject(s)
Hyperinsulinism/diagnosis , Hypoglycemia/diagnosis , Insulin/metabolism , Insulinoma/diagnosis , Kidney Neoplasms/complications , Nephrectomy/adverse effects , Neuroendocrine Tumors/complications , Female , Humans , Hyperinsulinism/etiology , Hypoglycemia/etiology , Insulin Secretion , Insulinoma/etiology , Insulinoma/metabolism , Kidney Neoplasms/metabolism , Kidney Neoplasms/surgery , Middle Aged , Neuroendocrine Tumors/metabolism , Neuroendocrine Tumors/surgery , Organometallic Compounds , Positron-Emission Tomography , PrognosisABSTRACT
More than 50% of patients with multiple endocrine neoplasia type 1 (MEN1) develop gastroenteropancreatic neuroendocrine tumors (GEPNETs), and insulinoma is the second most common functioning GEPNET. Compared to other functioning and nonfunctioning GEPNETs in MEN1, insulinoma is considered to develop at a younger age. To clarify the clinical features of insulinoma developed in Japanese patients with MEN1, a recently constructed database of Japanese MEN1 patients was analyzed. Among 560 registered cases, insulinoma was seen in 69 patients and information on age at diagnosis was available for 54 patients. Tumors predominantly occurred in the body and tail of the pancreas. The mean age at diagnosis of insulinoma (34.8 ± 16.7 yrs) was significantly younger than that of gastrinoma (50.6 ± 14.3 yrs) and nonfunctioning tumor (44.7 ± 13.3 yrs) in patients with MEN1. Patients diagnosed as having insulinoma during middle-age (30 - 49 yrs) tended to have a long period from appearance of hypoglycemic symptoms to diagnosis of the tumor. Of note, 13 patients (24%) were diagnosed as having insulinoma before 20 yrs of age. Such young onset was not seen in other GEPNETs. Since the development of GEPNETs during adolescence is quite rare, insulinoma diagnosed before 20 yrs strongly suggests the presence of MEN1 and warrants further investigation, including MEN1 genetic testing. Also, clinicians should be aware that insulinoma can often be missed in middle-aged patients.
Subject(s)
Insulinoma/epidemiology , Multiple Endocrine Neoplasia Type 1/complications , Multiple Endocrine Neoplasia Type 1/pathology , Adolescent , Adult , Age of Onset , Aged , Child , Databases, Factual , Female , Humans , Insulinoma/etiology , Insulinoma/pathology , Japan/epidemiology , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/epidemiology , Multiple Endocrine Neoplasia Type 1/genetics , Neuroendocrine Tumors/genetics , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathologyABSTRACT
Wilson's disease is a rare genetic disorder of copper metabolism. The difference in copper tissue accumulation is responsible for the various clinical manifestations of this disorder. If left untreated, Wilson's disease progresses to hepatic failure, severe neurological disability, and even death. Due to the complex clinical picture of Wilson's disease, its diagnosis relies on a high index of suspicion. In our paper, we present endocrine symptoms suggesting the presence of insulinoma and hyperprolactinemia as the initial clinical manifestation of Wilson's disease in a young female. Zinc acetate treatment resulted in the disappearance of hypoglycemia, galactorrhea, and menstrual abnormalities.
Subject(s)
Hepatolenticular Degeneration/diagnosis , Hyperprolactinemia/diagnosis , Insulinoma/diagnosis , Pancreatic Neoplasms/diagnosis , Amenorrhea/diagnosis , Amenorrhea/etiology , Diagnosis, Differential , Endocrine System/drug effects , Endocrine System/metabolism , Endocrine System/pathology , Female , Galactorrhea/diagnosis , Galactorrhea/etiology , Hepatolenticular Degeneration/complications , Hepatolenticular Degeneration/drug therapy , Humans , Hyperprolactinemia/etiology , Insulinoma/etiology , Pancreatic Neoplasms/etiology , Treatment Outcome , Young Adult , Zinc Acetate/therapeutic useABSTRACT
AIM: To perform a genetic screening for the multiple endocrine neoplasia type 1 (MEN1) gene mutations in patients affected by an apparently sporadic form of the disease, referred to an internal medicine unit of a large general hospital. SUBJECTS AND METHODS: In a group of 12 consecutive patients presenting clinical features of MEN type 1 syndrome, we performed a genetic screening for germline MEN1 gene mutations, including complete sequencing of the coding region (exons 2 to 10) and multiplex ligation-dependent probe amplification analysis for large deletion detection. RESULTS: Among these patients affected by apparently sporadic MEN type 1 syndrome, a targeted clinical history could detect indirect support for a diagnosis of familial condition only in 2 cases. The genetic screening identified pathogenic germline MEN1 gene mutations in 3 patients (25%). A previously unknown 18 base-pair deletion within exon 3, c.564_581delCAATGGGGAGCAGACAGC, resulting in loss of 6 amino acids (pAsp189_Ala194del), was found in heterozygosis in a woman affected by primary hyperparathyroidism and multifocal pancreatic neoplasia. CONCLUSIONS: Our results underscore the importance of performing genetic testing also in apparently sporadic MEN1 patients and extend the list of molecular variants leading to inactivation of the MEN1 gene.
Subject(s)
Multiple Endocrine Neoplasia Type 1/genetics , Proto-Oncogene Proteins/genetics , Sequence Deletion , Adenoma/etiology , Adenoma/genetics , Adult , Cohort Studies , DNA Mutational Analysis , Female , Humans , Insulinoma/etiology , Insulinoma/genetics , Italy , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/complications , Pancreatic Neoplasms/etiology , Pancreatic Neoplasms/genetics , Parathyroid Neoplasms/etiology , Parathyroid Neoplasms/genetics , Sequence Deletion/physiology , SyndromeABSTRACT
Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumors (NETs), which are usually benign, solitary and small. We describe herein a patient with a giant insulinoma (>10 cm in diameter) with concomitant thyroid tumor as detected by Somatostatin receptor scintigraphy (SRS). A 50-year-old man presented hypoglycemic symptoms 20 years after the first detection of a pancreatic tumor, which was ameliorated by administration of a somatostatin analogue, octreotide. SRS showed abnormal uptake by the insulinoma as well as by the thyroid tumor. RT-PCR and immunohistochemical study revealed abundant expression of somatostatin receptor (SSTR)-1, -2, and -5 in his insulinoma and SSTR-1 and -2 in his thyroid follicular neoplasm. This is a rare case of a slow-growing pancreatic well-differentiated neuroendocrine carcinoma over a long period of time to become a symptomatic giant insulinoma. Furthermore, SRS proves to be a useful tool for localization of insulinoma as well as concomitant thyroid neoplasm with predominant expression of SSTRs.
Subject(s)
Insulinoma/diagnosis , Pancreatic Neoplasms/diagnosis , Thyroid Neoplasms/diagnosis , Humans , Insulinoma/etiology , Male , Middle Aged , Pancreatic Neoplasms/complications , Thyroid Neoplasms/etiology , Time FactorsABSTRACT
OBJECTIVES: To identify gene expression alterations associated with insulinoma formation and progression in 2 mouse models of multiple endocrine neoplasia type 1. METHODS: Mice were killed at 12 or 16 months, and pancreatic islets were isolated by enzymatic and physical disruption. Islets were separated by size representing control, normal, hyperplastic, and adenomous islets. RNA was isolated from these islets and profiled on Sentrix Mouse-6 Expression version 1 BeadChips. Array data were analyzed in GeneSpring. RESULTS: One hundred and one genes that were significantly (P ≤ 0.05) altered in hyperplastic islets and insulinomas compared with normal islets were identified. Of these, 64 gene elements showed reduced messenger RNA levels and 37 gene elements had increased gene expression compared with control islets. Altered expression of 3 genes, namely, Gata6, Tspan8, and s100a8, was confirmed by quantitative reverse transcription-polymerase chain reaction, and aberrant levels of Tspan8 and Lmo2 protein measured by Western blot correlated with the changes in messenger RNA levels. CONCLUSIONS: These results suggest that alterations in gene expression of Gata6, Tspan8, S100a8, and Lmo2 may act via novel pathways that play functionally important roles in Men1-associated tumor progression.
Subject(s)
Gene Expression Profiling , Insulinoma/genetics , Multiple Endocrine Neoplasia Type 1/genetics , Pancreatic Neoplasms/genetics , Adaptor Proteins, Signal Transducing , Animals , Antigens, Neoplasm/genetics , Antigens, Neoplasm/metabolism , Blotting, Western , Calgranulin A/genetics , Calgranulin A/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Disease Progression , Female , GATA6 Transcription Factor/genetics , GATA6 Transcription Factor/metabolism , Humans , Insulinoma/etiology , Insulinoma/metabolism , Islets of Langerhans/metabolism , Islets of Langerhans/pathology , LIM Domain Proteins , Male , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Metalloproteins/genetics , Metalloproteins/metabolism , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Multiple Endocrine Neoplasia Type 1/complications , Multiple Endocrine Neoplasia Type 1/metabolism , Oligonucleotide Array Sequence Analysis , Pancreatic Neoplasms/etiology , Pancreatic Neoplasms/metabolism , Proto-Oncogene Proteins/deficiency , Proto-Oncogene Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , TetraspaninsSubject(s)
Autoimmunity , Diabetes Mellitus/etiology , Insulinoma/etiology , Animals , Humans , MiceABSTRACT
During diseases of the pancreas not only extrasecretory but also intrasecretory disorders are observed. The disturbances are dependent on excessive or insufficient releasing of hormones which are physiologically secreted by the pancreas. The most common endocrine disorder, which develops in pancreatic diseases, is insufficient insulin production which leads to carbohydrates balance disorders. The occurrence of endocrine pancreatic tumors (insulinoma, gastrinoma) is visibly less common--2-10% of neoplasmy of the organ. In group of endocrine tumors of the pancreas are also observed some changes which are able to release the vase-active intestinal peptide (VIP-oma), glucagon tumors, carcinoid released serotonine and somatostatinoma. More over, low-differentiated endocrine carcinomas of the pancreas consist about 1% of all pancreatic tumors and 2-3% of the all endocrine tumors.
Subject(s)
Pancreas/metabolism , Pancreatic Diseases/complications , Pancreatic Neoplasms/etiology , Diabetes Mellitus/etiology , Endocrine System Diseases/complications , Gastrinoma/etiology , Humans , Insulin/biosynthesis , Insulinoma/etiologyABSTRACT
The X-ray induction of tumors was examined in five-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats, treated with two 10 Gy doses to the gastric region with a 3-day interval (total 20 Gy). After irradiation, the rats received the commercial diet MF and tap water and were maintained for up to 564 days. The mean serum glucose level in the X-irradiated group was significantly lower than that in the non-irradiated animals at the 18 month time point. The total tumor incidence was 27/30 (87.1%) in the treated rats (islet tumors, gastric tumors, sarcomas, seminomas, adrenal tumors, kidney tumors, papilloma, lymphomas and mammary tumors). Islet tumors, generally showed to be positive for insulin by immunohistochemistry, developed in 19 rats (63.3%), and were associated with low serum glucose. Since spontaneous tumors observed in 6/19 (31.6%) rats (sarcomas, kidney tumors, duodenum tumors, seminoma, adrenal tumor and squamous cell carcinoma) did not include any insulinomas, these are clearly induced by X-irradiation in OLETF rats.
Subject(s)
Insulinoma/etiology , Neoplasms, Radiation-Induced/etiology , Pancreatic Neoplasms/etiology , Animals , Male , Rats , Rats, Inbred OLETF , Stomach/radiation effects , X-RaysABSTRACT
CONTEXT: The insulinoma syndrome is marked by fasting hypoglycemia and inappropriate elevations of insulin. The gastrinoma syndrome is characterized by hypergastrinemia, ulcer disease, and/or diarrhea. Rarely, insulinoma and gastrinoma coexist in the same patient simultaneously. OBJECTIVE: Our objective was to determine the cause of a patient's hypoglycemic episodes and peptic ulcer disease. DESIGN AND SETTING: This is a clinical case report from the Clinical Research Center of the National Institutes of Health. PATIENT AND INTERVENTION: One patient with hypoglycemic episodes and peptic ulcer disease had a surgical resection of neuroendocrine tumor. RESULTS: The patient was found to have a single tumor cosecreting both insulin and gastrin. Resection of this single tumor was curative. CONCLUSIONS: A single pancreatic neuroendocrine tumor may lead to the expression of both the hyperinsulinemic and hypergastrinemic syndromes.
Subject(s)
Gastrinoma/etiology , Insulinoma/etiology , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/etiology , Pancreatic Neoplasms/metabolism , Adolescent , Female , Gastrins/blood , Humans , Insulin/blood , Neuroendocrine Tumors/surgery , SyndromeABSTRACT
We surveyed 27 people who had adopted a total of 43 adult domestic ferrets after their use in a series of veterinary student surgery teaching laboratories to assess the success of those adoptions and to determine the rate of occurrence of common maladies of domestic ferrets after adult gonadectomy as compared with the usual practice of early-age gonadectomy. The adoptions took place 1-7 y prior to the survey. The response rate was 48% of adopters, covering 53% of the ferrets. Overall the success of former breeding and instructional ferrets as pets were rated as 91% good or excellent and 4.5% poor. Behavioral issues (for example, nipping, failure to litter train) were noted as the most common problems (36% of ferrets). Adrenal gland disease, insulinoma, or lymphosarcoma occurred in 23% of all ferrets and accounted for 57% of those ferrets that had died prior to the time of the survey.